Standardisation of Oral Liquid Ibuprofen suspension for improved stability and efficacy

dc.contributor.authorNyarko-Sefah, Nana Yaw
dc.date.accessioned2017-01-23T10:14:18Z
dc.date.accessioned2023-04-18T22:42:12Z
dc.date.available2017-01-23T10:14:18Z
dc.date.available2023-04-18T22:42:12Z
dc.date.issued2017-01-23
dc.descriptionA thesis submitted in fulfillment of the requirements for the award of Master of Philosophy (Pharmaceutics) to the Department of Pharmaceutics Faculty of Pharmacy and Pharmaceutical Sciences College of Health Sciences Kwame Nkrumah University of Science and Technology Kumasi, 2016.en_US
dc.description.abstractIbuprofen is a non-steroidal anti-inflammatory drug on the World Health Organization’s (WHO) Model list of Essential Medicines. Due to its peripheral anti-inflammatory action, ibuprofen is a useful drug in painful conditions associated with inflammation such as teething pain. This makes ibuprofen suspension one of the main analgesic, antipyretic and non-steroidal anti-inflammatory drugs available for paediatric care on the local market. Ernest Chemists Limited (ECL) a local pharmaceutical manufacturing company in Ghana ventured into the production of ibuprofen suspension. However the product was found to be unstable after 12months under real time stability studies. The focus of this work was to find the cause(s) of the instability of the ECL ibuprofen suspension and to optimise and reformulate a standardised and stable oral ibuprofen suspension. The procedures and properties of the ECL ibuprofen suspension were reviewed by examining the suspension from the raw material stage through processing, packaging, finished product specifications and storage conditions. The effect of environmental conditions such as storage temperature and light on the suspension was also investigated. Furthermore, the effects of product specific factors, like suspension pH on the stability of the product were also investigated. It was deduced from the results of the investigations that the absence of a buffering agent and an antioxidant may have accounted for the instability of the suspension. It was proposed to include a buffering agent and antioxidant in the recommended recipe. Citric acid-sodium citrate system was selected as the buffering agent, while ascorbic acid was chosen as the antioxidant. The one variable at a time (OVAT) principle was used to optimise the new formulation. The optimisation process led to the development of nine different formulations. One of the formulations was assessed as the best and selected as the preferred standard formulation for the ibuprofen suspension which was subjected to accelerated stability studies. The standardised formulation passed the accelerated stability studies pointing to a potentially stable product.en_US
dc.description.sponsorshipKNUSTen_US
dc.identifier.urihttps://ir.knust.edu.gh/handle/123456789/10156
dc.language.isoenen_US
dc.titleStandardisation of Oral Liquid Ibuprofen suspension for improved stability and efficacyen_US
dc.typeThesisen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
NANA YAW NYARKO-SEFAH_MPHil_2016.pdf
Size:
1.6 MB
Format:
Adobe Portable Document Format
Description:
Full Thesis
License bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.73 KB
Format:
Item-specific license agreed to upon submission
Description:
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: